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Despite the therapeutic efficacy of chimeric antigen receptor (CAR) redirected T cell immunotherapy in leukemia 
and lymphoma patients, similar clinical responses in solid tumor patients is, to date, an unrealized objective. We 
developed a CAR specific for CD171, an antigen expressed in several solid tumors including neuroblastoma, the 
most common extracranial tumor in childhood with an overall survival of less than 50% in high-risk patients. Since 
CD171 is also expressed in healthy tissues, including cerebellum and kidney, we proved the safety of targeting 
CD171 with CAR T cells in a non-human primate study. Further, we showed that CAR extracellular spacer and 
cytoplasmic signaling domain variants can be combined to tune the magnitude of cytotoxic CD8
+
 T lymphocyte 
(CTL) activation for tumor cell cytolysis and cytokine secretion. CAR constructs displaying the highest in vitro 
activity unexpectedly displayed the lowest in vivo anti-tumor activity, whereas CARs tuned for moderate signaling 
potency mediated tumor eradication. Recursively triggering hyperactive CARs rendered CTLs highly susceptible 
to activation-induced cell death resulting from augmented FasL expression, indicating that activation-induced cell 
death may be a critical parameter for achieving clinical efficacy against solid tumors. Our preclinical results 
assisted the design of a clinical trial comparing two CARs with different cytoplasmic signaling domains in patients 
with primary refractory or relapsed neuroblastoma, which was launched October 2014 at the Seattle Children's 
Hospital. 
